364 results on '"Subklewe, M."'
Search Results
2. Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
3. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study
4. P04.03 Immuno-analytics of patients with gastric cancer: impact of systemic polychemotherapy on peripheral T-cell fitness and immunologic features of gastric cancer tissue
5. P09.01 Adapting immune cells to the hypoglycemic tumor microenvironment by solute carrier 2a1 (Slc2a1/GLUT1) overexpression
6. Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
7. Axicabtagene ciloleucel (Axicel) for relapsed/refractory primary mediastinal B‐cell lymphoma (r/r PMBCL) compared to DLBCL‐NOS: A GLA/DRST registry study.
8. Gender Related Career Aspects in Pediatric Cardiology.
9. MO-0952 A multicentric retrospective analysis of the potential synergy between radiotherapy and CAR T-cells
10. Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML
11. Analyse der Diskordanz bildgebender Response Kriterien bei Lymphomen unter CAR-T-Zell-Therapie
12. Exploring risk factors for non-response to CAR T-cell therapy in large B-cell lymphoma: A binational multicenter project on potential predictors of outcome
13. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations
14. P08.05 Lentiviral protein Vpx delivery systems as potential weapons to improve cytarabine treatment response against acute myeloid leukemia
15. P09.01 Single-cell transcriptomic atlas-guided development of chimeric antigen-receptor (CAR) T cells for the treatment of acute myeloid leukemia
16. P09.02 Modular P329G-binding CAR T cells engineered to recognize human effector-silenced antibodies carrying a P329G Fc-mutation for targeting of solid tumor antigens
17. OS03.4.A In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer
18. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism
19. P1402: ALTERATIONS OF HUMAN BONE MARROW NICHE IN CLONAL HEMATOPOIESIS AND AML
20. P1458: PATTERNS OF LONG-TERM HEMATOPOIETIC RECOVERY IMPACT SURVIVAL OUTCOMES AFTER CD19-DIRECTED CAR T-CELL THERAPY FOR R/R LBCL
21. P356: SUBGROUP ANALYSES OF KTE-X19, AN ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL) IN ZUMA-3
22. P1445: MYTCELL®: AN INTERACTIVE SMARTPHONE APPLICATION FOR CARS AND BITES INCREASES GUIDELINE ACCESSIBILITY AND REDUCES TIME TO APPLY EVIDENCE-BASED PATIENT CARE
23. P433: ADAPTER HOLIDAYS MAINTAIN IN-VITRO ADCAR-T CELL FUNCTIONALITY AGAINST AML
24. P1438: PROCALCITONIN IS ELEVATED IN SEVERE INFECTIONS AFTER CD19 CAR-T IN R/R B-NHL AND ENABLES DISCRIMINATION OF EARLY INFECTIONS FROM CRS – PARTICULARLY IN COMBINATION WITH THE CAR-HEMATOTOX SCORE
25. P1447: INFERIOR OUTCOMES OF EU VS. US PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA AFTER CD19 CAR T-CELL THERAPY ARE IMPACTED BY BASELINE RISK FACTORS AND CAR PRODUCT CHOICE
26. PB2210: FAVORABLE OUTCOME AFTER SECOND CD19 CAR T INFUSION OF AN IDENTICAL PRODUCT: HOST ENVIRONMENT AND DISEASE CHARACTERISTICS DETERMINE THE OUTCOME OF TREATMENT
27. Prognosis and tumor biology of pancreatic cancer patients with isolated lung metastases: translational results from the German multicenter AIO-YMO-PAK-0515 study
28. Management of Adults and Children receiving CAR T-cell therapy: 2021 Best Practice Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
29. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia
30. Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse
31. Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
32. Management of adults and children receiving CAR T- cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
33. P07.03 ‘myTcell’: a smartphone applicationguides logisticsand management of CAR T-cell & BiTE related toxicities
34. P04.01 Immunomonitoring of CD19. CAR T-cells in Large B-Cell Lymphoma- a two-center experience
35. EXTRANODAL DISEASE IS ASSOCIATED WITH SHORTER PROGRESSION‐FREE SURVIVAL AFTER CD19‐CAR T‐CELL THERAPY FOR RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
36. CAR‐HEMATOTOX: A DISCRIMINATIVE MODEL FOR CAR T‐CELL RELATED HEMATOTOXICITY IN RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA
37. PHASE I STUDY OF THE CD19/CD3 HALF‐LIFE EXTENDED BITE ® MOLECULE AMG 562 IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA, MANTLE CELL LYMPHOMA AND FOLLICULAR LYMPHOMA
38. 2021 update measurable residual disease in acute myeloid leukemia: European leukemia net working party consensus document
39. RICarT : Registry for immune-effector and CAR T associated toxicities
40. Fusion of bacterial flagellin to a dendritic cell-targeting alpha CD40 antibody construct coupled with viral or leukemia-specific antigens enhances dendritic cell maturation and activates peptide-responsive T cells
41. Toll‐like receptor 7/8‐matured RNA‐transduced dendritic cells as post‐remission therapy in acute myeloid leukaemia: results of a phase I trial
42. Extramedullary manifestation of a donor-derived acute myeloid leukemia in a liver transplant patient
43. P04.09 Development of a dendritic cell vaccine against hepatocellular carcinoma using VSV-NDV
44. L4 Synthetic agonistic receptor-activating BiTEs – a modular platform for the efficient targeting of acute myeloid leukemia
45. P04.04 Multifunctional antibody construct for in vivo targeting of dendritic cells as a therapeutic vaccination strategy in AML
46. P09.12 Bifunctional SIRPα-CD123 fusion antibody for the elimination of acute myeloid leukemia stem cells
47. P02.01 Predictive impact of the gut microbiota on treatment response to CD19 specific CAR T-cells
48. P07.01 CD19 CAR T-cells for relapsed/refractory diffuse large B-cell Lymphoma: real-world data from LMU Munich
49. Predicting yields in autologous MNC apheresis for ATMP manufacture: applying a kinetic model for HPC apheresis
50. Monoallelic CEBPA mutations in normal karyotype AML: Additional gene mutations predict outcome: V29
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.